See more : Aigan Co.,Ltd. (9854.T) Income Statement Analysis – Financial Results
Complete financial analysis of Rezolute, Inc. (RZLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rezolute, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- WOLVES HAND CO LTD (194A.T) Income Statement Analysis – Financial Results
- Opsens Inc. (OPSSF) Income Statement Analysis – Financial Results
- Nichi-Iko Pharmaceutical Co., Ltd. (4541.T) Income Statement Analysis – Financial Results
- Tsukiji Uoichiba Company, Limited (8039.T) Income Statement Analysis – Financial Results
- Microsoft Corporation (4338.HK) Income Statement Analysis – Financial Results
Rezolute, Inc. (RZLT)
About Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 36.00K | 382.00K | 256.00K | 303.00K | 18.00K | 48.00K | 1.07M | 12.57M | 8.27M | 5.85M | 2.40M | 4.56M | 4.84K |
| Gross Profit | -36.00K | -382.00K | -256.00K | -303.00K | -18.00K | -48.00K | -1.07M | -12.57M | -8.27M | -5.85M | -2.40M | -4.56M | -4.84K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 55.74M | 43.81M | 32.49M | 14.99M | 14.45M | 19.08M | 17.28M | 12.09M | 9.45M | 4.70M | 34.32K | 3.49K | 0.00 |
| General & Administrative | 196.00K | 12.18M | 9.36M | 7.91M | 6.07M | 6.82M | 9.10M | 8.23M | 5.50M | 6.00M | 5.13M | 6.10M | 42.67M |
| Selling & Marketing | 14.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -42.63M |
| SG&A | 14.64M | 12.18M | 9.36M | 7.91M | 6.07M | 6.82M | 9.10M | 8.23M | 5.50M | 6.00M | 5.13M | 6.10M | 42.67K |
| Other Expenses | 0.00 | 0.00 | -231.00K | -515.00K | 0.00 | 321.00K | 136.13K | 37.14K | 5.33M | 3.51M | 11.30K | 295.00 | 6.62M |
| Operating Expenses | 70.42M | 55.99M | 41.61M | 22.38M | 20.52M | 25.90M | 26.38M | 20.32M | 14.95M | 10.70M | 5.18M | 6.11M | 42.67K |
| Cost & Expenses | 70.42M | 55.99M | 41.61M | 22.38M | 20.52M | 25.90M | 26.38M | 20.32M | 14.95M | 10.70M | 5.18M | 6.11M | 47.51K |
| Interest Income | 0.00 | 4.21M | 80.00K | 63.00K | 188.00K | 61.00K | 1.00K | 0.00 | 965.00 | 4.97K | 12.18K | 106.04K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.81M | 375.00K | 0.00 | 4.96M | 689.19K | 1.60K | 5.04K | 6.73K | 4.23M | 568.86K | 0.00 |
| Depreciation & Amortization | 36.00K | 382.00K | 256.00K | 303.00K | 18.00K | 48.00K | 1.07M | 1.11M | 751.25K | 134.13K | 11.30K | 295.00 | 221.00 |
| EBITDA | -68.42M | -51.41M | -41.83M | -22.88M | -20.32M | -25.44M | -28.11M | -19.16M | -14.18M | -11.22M | -5.49M | -6.16M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -70.42M | -55.99M | -41.84M | -22.89M | -20.52M | -25.94M | -28.73M | -20.32M | -14.95M | -10.70M | -5.18M | -6.11M | -45.73K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.96M | 4.20M | 783.00K | 1.99M | 188.00K | -4.50M | -1.13M | 46.92K | 15.75K | -664.48K | -4.55M | -620.58K | -1.78K |
| Income Before Tax | -68.46M | -51.79M | -41.06M | -20.90M | -20.33M | -30.45M | -29.86M | -20.28M | -14.94M | -11.36M | -9.73M | -6.73M | -47.51K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -137.90K | -2.28M | 375.00K | -297.00 | -29.00K | 2.93M | -11.37K | -19.82K | 662.72K | 336.49K | 157.76K | 3.56K |
| Net Income | -68.46M | -51.79M | -38.78M | -21.28M | -20.33M | -30.42M | -29.86M | -20.28M | -14.94M | -11.36M | -9.73M | -6.73M | -49.29K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.33 | -1.01 | -2.13 | -2.77 | -3.54 | -17.11 | -26.83 | -24.55 | -30.14 | -27.12 | -51.84 | -54.21 | -0.64 |
| EPS Diluted | -1.33 | -1.01 | -1.99 | -2.77 | -3.54 | -17.11 | -26.83 | -24.55 | -30.14 | -27.12 | -51.84 | -54.21 | -0.64 |
| Weighted Avg Shares Out | 51.47M | 51.19M | 18.20M | 7.67M | 5.75M | 1.78M | 1.11M | 825.93K | 495.46K | 419.00K | 187.69K | 124.09K | 77.35K |
| Weighted Avg Shares Out (Dil) | 51.47M | 51.19M | 19.49M | 7.67M | 5.75M | 1.78M | 1.11M | 825.93K | 495.46K | 419.00K | 187.69K | 124.09K | 77.35K |
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its underwritten public offering of 11,250,000 shares...
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of its previously announced underwritten public offering of...
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it is commencing an underwritten public offering of shares...
Rezolute to Participate in the Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that Nevan Charles Elam, Chief Executive Officer...
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual investor event to be held today at 5:30pm ET REDWOOD...
$DED: What Do We Know So Far?
The last few months have seen the Polkadot network come back to life, and ironically, a project called “Dot is Ded” is behind that. Backed by the $DED token, this grassroots memecoin has gone out of its way to get...
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Analysis of...
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio.
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism)
Source: https://incomestatements.info
Category: Stock Reports